7,550.50

-24.00

-0.32%

51,816.00

-317.00

-0.61%

28,082.75

-44.75

-0.16%

Russell 2000 Futures

2,807.80

-10.00

-0.35%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.91%

3,917.30

-52.30

-1.32%

76,761.32

-1,226.76

-1.57%

Crude Oil Dec 26

98.13

+1.67

+1.73%

US Private Equity

10,836.30

-14.33

-0.13%

OTC Markets OTCPK - Delayed Quote USD

Idorsia Ltd (IDRSF)

4.9500 -0.4300 (-7.99%)

At close: October 30 at 4:00:00 PM EDT

Loading Chart for IDRSF

Chart Range Bar

Interval:

In partnership with ChartIQ

Invitation to Idorsia's webcast and conference call to provide more context on the opportunity and launch approach for TRYVIO/JERAYGO

Invitation to Idorsia's webcast and conference call to provide more context on the opportunity and launch approach for TRYVIO/JERAYGO

Idorsia reports accelerating QUVIVIQ growth, advances key value drivers, and reaffirms full-year financial guidance

Idorsia reports accelerating QUVIVIQ growth, advances key value drivers, and reaffirms full-year financial guidance

Idorsia and SPV investors partner to unlock the blockbuster potential of TRYVIO/JERAYGO with a targeted launch in specialists

Idorsia and SPV investors partner to unlock the blockbuster potential of TRYVIO/JERAYGO with a targeted launch in specialists

Nxera Pharma Secures Exclusive Rights to Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat for Japan and Selected Asia Pacific Markets

Nxera Pharma Secures Exclusive Rights to Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat for Japan and Selected Asia Pacific Markets

Idorsia initiates pivotal Phase 3 study for lucerastat in Fabry disease and enters co-development and commercialization agreement with Nxera

Idorsia initiates pivotal Phase 3 study for lucerastat in Fabry disease and enters co-development and commercialization agreement with Nxera

Idorsia seeks US label update for QUVIVIQ daytime functioning benefits – first patients enrolled in Dari-Dream

Idorsia seeks US label update for QUVIVIQ daytime functioning benefits – first patients enrolled in Dari-Dream

A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder

A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder

Idorsia presents outstanding results with daridorexant in children and adolescents with insomnia and an expanding body of evidence in adults at Sleep Europe 2026

Idorsia presents outstanding results with daridorexant in children and adolescents with insomnia and an expanding body of evidence in adults at Sleep Europe 2026

Aprocitentan efficacy data reinforce endothelin pathway blockade as a distinct therapeutic approach across the cardiometabolic disease spectrum including obesity

Aprocitentan efficacy data reinforce endothelin pathway blockade as a distinct therapeutic approach across the cardiometabolic disease spectrum including obesity

New results across pediatric, adult and real-world insomnia settings highlight the expanding clinical evidence for daridorexant at Sleep Europe 2026

New results across pediatric, adult and real-world insomnia settings highlight the expanding clinical evidence for daridorexant at Sleep Europe 2026

Efficacy of aprocitentan in patients across the cardiometabolic disease spectrum including obesity to be presented at AHA Hypertension

Efficacy of aprocitentan in patients across the cardiometabolic disease spectrum including obesity to be presented at AHA Hypertension

Mobilize your Website

View Site in Mobile | Classic

Share by: